Research Overview
Nicotinamide riboside (NR) has been most studied as an oral nicotinamide adenine dinucleotide (NAD+) precursor with potential relevance to aging biology, mitochondrial function, and inflammatory or degenerative conditions in which NAD+ depletion and DNA damage are implicated. Human research has commonly focused on pharmacodynamic endpoints—especially whether NR raises NAD+ or related metabolites in accessible tissues such as whole blood—alongside exploratory biomarkers of inflammation, oxidative stress, and “biological aging” signatures (e.g., transcriptomic or epigenetic measures). The COPD trial described adds to this translational pattern by testing NR in a disease context linked to aging and smoking-related damage, using both a clinical inflammatory biomarker (sputum IL-8) and mechanistic readouts (blood NAD+, airway gene pathways, epigenetic aging indices).
The strongest evidence currently supports that NR supplementation can increase systemic NAD+ levels in humans, as demonstrated here by a more than twofold rise in whole-blood NAD+ after 6 weeks. In this randomized, double-blind, placebo-controlled COPD study (n = 40), NR was also associated with a statistically significant reduction in sputum IL-8 at 6 weeks versus placebo, with the effect persisting 12 weeks after treatment cessation, suggesting a potential anti-inflammatory impact in the airways. However, not all inflammatory markers moved in parallel (plasma IL-6 was unchanged), indicating that effects may be pathway-, compartment-, or disease-specific rather than broadly anti-inflammatory.
Key areas needing more research include replication in larger, longer-duration trials; clarification of clinically meaningful outcomes (e.g., symptoms, exacerbation frequency, lung function decline, hospitalization, and mortality in COPD) beyond biomarker changes; and better mapping of tissue-specific NAD+ repletion and downstream mechanisms in target organs (e.g., airway epithelium and immune cells). The exploratory signals reported—upregulation of genomic integrity pathways and reduced epigenetic aging potentially via reduced cellular senescence—are hypothesis-generating and require confirmation with prespecified endpoints, standardized assays, and mechanistic validation. Overall, the field has relatively strong evidence for NAD+ augmentation in humans, emerging but still limited evidence for disease-modifying biomarker effects in specific conditions, and insufficient evidence to conclude broad clinical benefit across aging-related diseases without further rigorous trials.
1. What conditions has Nicotinamide Riboside been studied for?
Chronic obstructive pulmonary disease (COPD): Studied in a randomized, double-blind, placebo-controlled clinical trial in patients with stable COPD (n = 40) treated for 6 weeks, with follow-up 12 weeks after stopping treatment.
Biological aging-related processes (exploratory, within COPD context): The study reports exploratory analyses related to DNA damage/genomic integrity, epigenetic aging, and cellular senescence in airway samples, framed as mechanisms relevant to aging and COPD.
2. Does it work in treating those conditions? Summarize the evidence.
-
COPD airway inflammation (biomarker outcome): In the trial, the primary endpoint (change in sputum IL-8 at 6 weeks) improved with NR versus placebo.
Estimated treatment difference in sputum IL-8 after 6 weeks: -52.6% (95% CI: -75.7% to -7.6%; P = 0.030).
Effect persisted 12 weeks after end of treatment: -63.7% (95% CI: -85.7% to -7.8%; P = 0.034).
-
Systemic inflammation: Plasma IL-6 was a secondary outcome and was unchanged with NR in this study.
-
Clinical outcomes (symptoms, lung function, exacerbations): The study does not report improvements in clinical endpoints; it focuses on inflammatory biomarkers and mechanistic/exploratory signals. Therefore, evidence for “treating COPD” in a clinical sense remains incomplete based on this study alone.
-
Mechanistic/aging-related signals (exploratory): The study reports “indications” of upregulated gene pathways related to genomic integrity in the airways and reduced epigenetic aging, possibly via reduced cellular senescence, but explicitly notes these exploratory findings require confirmation in future trials.
3. What health benefits does it have?
-
Raises NAD+ levels: NR increased NAD+ levels by more than twofold in whole blood (secondary outcome), supporting its role as an NAD+ precursor in humans.
-
Reduced airway inflammatory signaling in COPD (biomarker): NR reduced sputum IL-8 versus placebo at 6 weeks, with persistence at 12-week post-treatment follow-up in this trial.
-
Potential benefits related to genomic integrity and biological aging (exploratory): The study reports indications of:
Upregulated airway gene pathways related to genomic integrity.
Reduced epigenetic aging, possibly through reduced cellular senescence.
These are hypothesis-generating and not yet confirmed as established benefits.
4. Does it have any downsides or side effects?
The study does not describe adverse events, tolerability, discontinuation rates, or specific side effects. Based on this study alone:
Known downsides/side effects cannot be determined from the information provided.
Evidence limitation: Absence of reported side effects in the study is not evidence of absence; safety conclusions require adverse event reporting and larger/longer trials.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The study does not report analyses stratified by genotype or specific genetic variants affecting response or safety (e.g., NAD+ metabolism genes, inflammatory pathway variants).
No pharmacogenomic conclusions can be drawn from this study.
Exploratory gene pathway findings (genomic integrity pathways) are not the same as pharmacogenomic effects tied to inherited genetic variation.
References
-
Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial
Kristoffer L Norheim, Michael Ben Ezra, Indra Heckenbach, Louise Munkholm Andreasson, Lise Lotte Eriksen (2024)
This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!